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Introduction. Many patients with non-alcoholic fatty liver disease (NAFLD) have impaired glucose regulation or type 2 diabetes
mellitus (DM). We investigated characteristics of NAFLD patients associated with hyperglycemia. Methods. During a 2-hour oral
glucose tolerance test (OGTT), serum glucose and insulin were measured in 152 NAFLD patients. Results. 48.7% of NAFLD
patients had hyperglycemia. Age (odds ratio (OR) = 1.08, 95% conﬁdence interval (CI): 1.03–1.13), body mass index (BMI)
(OR = 1.12, 95% CI: 1.01–1.25), and lower high-density lipoprotein cholesterol (HDL-C) (OR = 0.95, 95% CI: 0.92–0.98) proved
to be independent predictors of hyperglycemia. After OGTT, 30min insulin was lower in hyperglycemic patients (74.2 ± 49.7
versus 94.5±53.9μIU/mL, P = 0.02), while 90min insulin (170.1±84.6 versus 122.9±97.7μU/mL, P = 0.01) and 120min insulin
(164.0 ± 101.2v e r s u s8 5 .3 ± 61.9μIU/mL, P<0.01) were higher. Conclusions. NAFLD patients with higher BMI, lower HDL-C,
or older age were more likely to have impaired glucose metabolism. An OGTT could be of value for early diagnosis of DM among
this population.
1.Introduction
Non-alcoholic fatty liver disease is increasingly being iden-
tiﬁed in routine clinical practice [1]. Although the natural
history of this disorder is variable, the presence of non-
alcoholic fatty liver disease may lead to an adverse prognosis
for some patients, due to liver-related disorders, as well as
cardiovascular morbidity and mortality [2–4]. The patho-
genesis of non-alcoholic fatty liver disease has been closely
relatedtoinsulinresistance;thisdisorderfrequentlyco-exists
with impaired glucose tolerance (IGT) or type 2 diabetes
mellitus [5–7]. The latter conditions, if present, have been
associated with more severe liver disease and unfavorable
prognosis [8–11].
Screening patients with non-alcoholic fatty liver disease
for impaired glucose regulation or type 2 diabetes mellitus
could help the earlier diagnosis and treatment of these
conditions preventing their possible complications, such
as cardiovascular diseases. The measurement of fasting
plasma glucose is considered as the preferred initial screen-
ing test for the identiﬁcation of hyperglycemia [12]. The
sensitivity of this test can be variable depending on the
population evaluated [13, 14]. However, it has not been
clearly established, which of the patients with non-alcoholic
fatty liver disease should further undergo an oral glucose
tolerance test for the above-described purposes. In this
regard, we sought to identify predictor characteristics for the
presence of impaired glucose regulation or type 2 diabetes2 Experimental Diabetes Research
in patients with non-alcoholic fatty liver disease and assess
for potential diﬀerences in these patients regarding glucose
metabolism.
2. Methods
We prospectively studied a cohort of patients who presented
with elevated levels of serum aminotransferases at the
outpatient hepatology clinic of Attikon University Hospital,
in Athens, Greece, between June 2006 and September 2009,
andwasdiagnosedwithnon-alcoholicfattyliverdisease.The
diagnosisofnon-alcoholicfattyliverdiseasewasbasedonthe
presence of hypertransaminasemia along with characteristic
ﬁndings of fatty inﬁltration in liver ultrasonography (“bright
liver” or hyperechoic appearance) and the exclusion of
other possible causes of hypertransaminasemia, including
alcoholicliverdisease,adverseeventsofdrugs,viralhepatitis,
autoimmune disorders, and hereditary diseases aﬀecting the
liver.
The patients that were diagnosed with non-alcoholic
fatty liver disease underwent an oral glucose tolerance test,
unless they had a known prior history of diabetes or a fasting
serum glucose ≥126mg/dL. Speciﬁcally, 75g of glucose were
administered orally after an overnight fast. Serum glucose
and insulin were measured in blood samples obtained
through an indwelling peripheral vein cannula at time 0
and 30, 60, 90, and 120min after the glucose challenge.
Patients were classiﬁed as having normoglycemia (normal
glucose values), impaired fasting glucose (IFG), IGT, or
type 2 diabetes, according to the criteria endorsed by the
American Diabetes Association [15]. Approval for the study
was granted by the institutional review board.
2.1. Data Analysis. We grouped the non-alcoholic fatty
liver disease patients into normoglycemic and hyperglycemic
(IFG,IGT,ortype2diabetes).Weassessedforthepresenceof
diﬀerences between the above 2 groups in the patient demo-
graphics, body mass index (BMI), and common laboratory
tests. We also assessed for diﬀerences between the 2 groups
in the levels of glucose and insulin obtained at the 5 time
points speciﬁed above during the 75g oral glucose tolerance
test and the overall insulin response during the test. The
overall insulin response was determined on the basis of the
area under the curve (AUC) of insulin levels versus time,
extracting the area corresponding to the baseline insulin
level (net incremental insulin AUC). We used the trapezoid
method to calculate the AUC. Finally, we calculated the
updated homeostasis model assessment of insulin resistance
(HOMA2-IR) index and assessed for diﬀerences between the
2g r o u p s[ 16]. We used the independent samples t-test and
the x2-test to compare continuous and categorical variables,
respectively. The variables of baseline patient characteristics
with diﬀerent distributions between the normoglycemic and
hyperglycemic groups were entered in a stepwise, forward,
binary logistic regression model to test for independent
associations. P values lower than 0.05 were considered
statistically signiﬁcant. We used the SPSS version 15.0 (SPSS
Inc., Chicago, ILL) as the software for the statistical analysis.
3. Results
A total of 152 Caucasian patients (52.0% females and 48%
males) with non-alcoholic fatty liver disease, with mean ±
standard deviation age of 50.1 ± 11.4 years were included in
the study. According to the values of fasting serum glucose or
serum glucose 2 hours after the 75g oral glucose challenge,
78ofthe152patients(51.3%)werenormoglycemic,while45
patients (29.6%) had IFG or IGT (21 and 41 patients, resp.),
and 29 (19.1%) had type 2 diabetes (Figure 1).
InTable 1,wedescribethebaselinepatientcharacteristics
and common laboratory tests in non-alcoholic fatty liver
disease patients with or without hyperglycemia. Age, BMI,
high-density lipoprotein cholesterol (HDL-C), and serum
albumin were the only variables that signiﬁcantly diﬀered
between the 2 studied groups. In the multivariate analysis
thatincludedtheabovefourvariablesascovariates,age(odds
ratio: 1.08, 95% conﬁdence interval: 1.03–1.13), BMI (odds
ratio: 1.12, 95% conﬁdence interval: 1.01–1.25), and HDL-
C (odds ratio: 0.95, 95% conﬁdence interval: 0.92–0.98)
were found to be independently associated with the presence
of hyperglycemia in patients with non-alcoholic fatty liver
disease. Patients with hyperglycemia had greater age (53.0 ±
10.7 versus 47.3 ± 11.4 years, P<0.01), higher BMI (30.5
± 4.5 versus 28.5 ± 4.8kg/m2, P = 0.01), lower HDL-C
(46.5 ± 13.6 versus 53.7 ± 18.8mg/dL, P = 0.02), and lower
serum albumin (4.1 ± 0.5 versus 4.4 ± 0.4g/dL, P<0.01) in
comparison to patients with normoglycemia (Figure 1).
Table 2 depicts the associations of serum glucose and
insulin values obtained at time 0 and 30, 60, 90, and 120min
after the 75g oral glucose load between non-alcoholic fatty
liverdiseasepatientswithorwithouthyperglycemia.Patients
with hyperglycemia (IFG, IGT, or type 2 diabetes) had
higher glucose values at all the above-speciﬁed time points
compared with patients without hyperglycemia. Addition-
ally, patients with hyperglycemia showed signiﬁcantly higher
insulin levels at time 0, 90, and 120min compared with
patients without hyperglycemia. Insulin at 30min was lower
in the patients with hyperglycemia, and insulin at 60min
did not diﬀer between the 2 groups. The overall insulin
response (net incremental insulin AUC) did not diﬀer, as
well. The HOMA2-IR index signiﬁcantly diﬀered between
the two groups (Table 2).
4. Discussion
Almost half (48.7%) of the patients with non-alcoholic
fatty liver disease who were evaluated in our study and
had IFG, IGT, or type 2 diabetes. This group was of older
age had higher BMI, lower levels of HDL-C, and lower
serumalbumincompared withthe group of patients without
hyperglycemia. Age, BMI, and HDL-C were independent
predictors of the presence of IFG, IGT, or type 2 diabetes in
our cohort of patients with non-alcoholic fatty liver disease.
The patients with hyperglycemia seemed to be more insulin
resistant compared with those without hyperglycemia. The
acute phase of insulin response to the 75g oral glucose
load was less pronounced in the hyperglycemic group, as
evidenced by insulin at 30min. This was followed by moreExperimental Diabetes Research 3
DM: type 2 diabetes mellitus, IFG: impaired fasting glucose, IGT: impaired
glucose tolerance.
Cell shaded in white indicates the 78 patients with normoglycemia.
Cells shaded in light grey indicate the 45 patients with IFG or IGT.
Cells shaded in dark grey indicate the 29 patients with DM.
2-hour serum glucose after 75-g oral glucose challenge
Normal glucose
tolerance
IGT DM
N
Fasting serium glucose
ormal fasting glucose 78 33 16
IFG 489
DM 0 04
Figure 1: Classiﬁcation of the 152 included patients with non-alcoholic fatty liver disease on the basis of fasting serum glucose and 2-hour
post-load serum glucose.
Table 1: Baseline characteristics of non-alcoholic fatty liver disease patients with and without hyperglycemia.
Patient
characteristics IFG/IGT, n = 45 DM, n = 29 Hyperglycemia
(IFG/IGT or DM), n = 74
Normoglycemia,
n = 78
P value
(patients with hyperglycemia
versus normoglycemia)
n/N (%) OR mean ± standard deviation
Sex, Female 21/45 (46.7%) 14/29 (48.3%) 35/74 (47.3%) 44/78 (56.4%) 0.26
Age, years 51.2 ± 10.2 55.9 ± 11.0 53.0 ± 10.7 47.3 ± 11.4 <0.01
Body mass index,
kg/m2 30.0 ± 4.2 31.1 ± 4.9 30.5 ± 4.5 28.5 ± 4.8 0.01
AST, U/L 43.7 ± 46.6 38.8 ± 23.5 41.7 ± 38.8 40.2 ± 33.4 0.81
ALT, U/L 64.6 ± 45.9 59.8 ± 39.1 62.7 ± 38.8 67.7 ± 55.6 0.55
AST/ALT ratio 0.68 ± 0.22 0.72 ± 0.30 0.70 ± 0.25 0.71 ± 0.39 0.85
GGT, U/L 86.7 ± 70.8 89.6 ± 87.1 87.9 ± 77.2 86.6 ± 88.7 0.92
Cholesterol, mg/dL 209.4 ± 40.7 209.2 ± 50.8 209.3 ± 44.6 211.9 ± 42.3 0.74
Triglycerides,
mg/dL 135.1 ± 64.5 146.4 ± 76.2 139.7 ± 69.1 123.1 ± 72.3 0.18
HDL-C, mg/dL 47.6 ± 14.3 45.0 ± 12.7 46.5 ± 13.6 53.7 ± 18.8 0.02
LDL-C, mg/dL 128.3 ± 32.1 131.2 ± 40.3 129.6 ± 35.8 133.9 ± 34.1 0.51
Triglycerides/HDL-
Cr a t i o 3.6 ± 3.4 3.6 ± 2.2 3.6 ± 2.9 2.7 ± 2.2 0.05
Total Protein, g/dL 7.0 ± 1.5 7.0 ± 1.6 7.0 ± 1.5 7.1 ± 1.7 0.83
Albumin, g/dL 4.2 ± 0.4 4.0 ± 0.5 4.1 ± 0.5 4.4 ± 0.4 <0.01
Albumin/globulin
ratio 3.1 ± 7.9 1.8 ± 1.7 2.5 ± 6.1 2.3 ± 3.1 0.83
Hemoglobin, g/dL 14.4 ± 1.5 13.6 ± 1.7 14.0 ± 1.6 14.1 ± 1.4 0.93
Hematocrit, % 43.4 ± 4.6 41.8 ± 4.2 42.7 ± 4.5 42.2 ± 3.8 0.45
ALT:alanineaminotransferase,AST:aspartateaminotransferase,DM:type2diabetesmellitus,IFG:impairedfastingglucose,IGT:impairedglucosetolerance,
GGT: gamma-glutamyl transpeptidase, HDL-C: high-density lipoprotein cholesterol, IFG: impaired fasting glucose, and IGT: impaired glucose tolerance.4 Experimental Diabetes Research
Table 2: Glucose and insulin regulation in response to a 75g oral glucose tolerance test in non-alcoholic fatty liver disease patients with and
without hyperglycemia.
Patient
characteristics IFG/IGT, n = 45 DM, n = 29 Hyperglycemia
(IFG/IGT or DM), n = 74
Normoglycemia,
n = 78
P value
(patients with hyperglycemia
versus normoglycemia)
Mean ± standard deviation
Glucose 0min,
mg/dL 89.9 ± 14.1 104.0 ± 21.9 95.4 ± 18.7 80.9 ± 10.5 <0.01
Insulin 0min,
μIU/mL 15.4 ± 8.3 19.5 ± 10.2 17.0 ± 9.3 13.8 ± 7.2 0.02
Glucose 30min,
mg/dL 160.4 ± 27.0 179.9 ± 42.1 167.7 ± 34.6 147.8 ± 32.5 <0.01
Insulin 30min,
μIU/mL 79.5 ± 53.4 65.3 ± 42.3 74.2 ± 49.7 94.5 ± 53.9 0.02
Glucose 60min,
mg/dL 204.5 ± 34.9 241.7 ± 40.3 219.1 ± 41.1 152.9 ± 39.0 <0.01
Insulin 60min,
μIU/mL 133.1 ± 72.0 112.4 ± 70.7 125.0 ± 71.7 136.7 ± 88.8 0.38
Glucose 90min,
mg/dL 196.9 ± 37.4 264.1 ± 38.9 219.8 ± 49.4 126.9 ± 32.9 <0.01
Insulin 90min,
μIU/mL 163.6 ± 80.0 183.0 ± 95.1 170.1 ± 84.6 122.9 ± 97.7 0.01
Glucose 120min,
mg/dL 163.2 ± 24.2 243.6 ± 38.3 194.7 ± 49.8 105.4 ± 21.7 <0.01
Insulin 120min,
μIU/mL 160.9 ± 96.3 168.8 ± 110.1 164.0 ± 101.2 85.3 ± 61.9 <0.01
Net incremental
insulin AUC,
μIU/mL ∗ min
11872.9 ±
6608.2
10545.7 ±
6688.5 11352.8 ± 6626.1 10285.4 ±
6690.6 0.33
HOMA2-IR index 1.9 ± 1.0 2.5 ± 1.3 2.2 ± 1.2 1.7 ± 0.9 <0.01
AUC: area under the curve, HOMA2-IR: homeostasis model assessment of insulin resistance, DM: type 2 diabetes mellitus, IFG: impaired fasting glucose,
IGT: impaired glucose tolerance, and LDL-C: low-density lipoprotein cholesterol.
pronounced hyperinsulinemia at 90 and 120min after the
glucose challenge.
Our study ﬁndings agree with those of other studies
that have showed variability in the glucose regulation of
patients with non-alcoholic fatty liver disease [10]. This
could be in part attributed to the fact that non-alcoholic
fatty liver disease comprises a spectrum of disorders of
diﬀerent severity, from simple hepatic steatosis to non-
alcoholic steatohepatitis, hepatic ﬁbrosis, and cirrhosis [6].
In our study, older age was associated with a greater
likelihood for impaired glucose regulation in patients with
non-alcoholic fatty liver disease. Type 2 diabetes mellitus is
known to be associated with older age, a fact that reﬂects
the long process for clinical onset of diabetes mellitus [14]. It
canbeassumedthatmetabolicderangementsassociatedwith
non-alcoholic fatty liver disease and insulin resistance [17,
18] impose a stress on pancreatic β-cells that may eventually
fail to compensate for the increased insulin requirements.
In our study, the acute insulin response to the oral glucose
load, which can be considered as a marker of β-cell function
[19, 20], was found to be decreased in non-alcoholic fatty
liver disease patients with hyperglycemia.
Higher BMI is also a known risk factor for type 2
diabetes mellitus [21]. In our study higher BMI indepen-
dently predicted the risk for the presence of hyperglycemia
among patients with non-alcoholic fatty liver disease [17].
More than half of our study population had a BMI below
the threshold of 30kg/m2 though. Therefore, our ﬁndings
should not be interpreted as if only obese patients with non-
alcoholic fatty liver disease have hyperglycemia.
Serum levels of HDL-C were also lower in the subgroup
of patients with hyperglycemia of the non-alcoholic fatty
liver disease patients evaluated in our study. Low HDL-C
is a characteristic ﬁnding in diabetic dyslipidemia and is
alsoassociatedwithprediabetes,insulinresistance,metabolic
syndrome, and non-alcoholic fatty liver disease [20, 22–
24]. The elevated levels of serum triglycerides, another
feature of diabetic dyslipidemia, did not seem to diﬀer
between the non-alcoholic fatty liver disease patients who
had hyperglycemia compared with those who did not, in
our study. Also, comparison of the two groups on the basis
of the ratio triglycerides/HDL-C, a parameter that has been
associatedwithinsulinresistanceandatherogenicity[25,26],
showed only a marginal diﬀerence (Table 1).Experimental Diabetes Research 5
Additionally, in our study, the non-alcoholic fatty liver
disease patients with hyperglycemia had lower levels of
serumalbumincomparedwiththosewithouthyperglycemia,
although this diﬀerence was not independent of age, BMI,
and HDL-C. Presumably, lower serum albumin in patients
with non-alcoholic fatty liver disease could also be related
to more advanced liver disease, higher degree of systemic
inﬂammation, or albuminuria due to diabetic nephropathy
[8, 27].
Screening for hyperglycemia could be considered in
patients with non-alcoholic fatty liver disease given the
strong association of this disorder with IGT, including
diabetes mellitus. There are known risk factors for type
2 diabetes to guide the selection of patients to screen
[12]. Age above 45 years and the association of a BMI
above 25kg/m2 with HDL-C below 35mg/dL are among the
indicators for screening for type 2 diabetes proposed by the
American Diabetes Association [12] .I no u rs t u d y ,a g e ,B M I ,
and HDL were independent indicators for the presence of
impaired glucose regulation in patients with non-alcoholic
fattyliverdiseasewhohadnoknownderangementinglucose
metabolism.
If our patients had undergone assessment of fasting
serum glucose alone, 25 of the 74 (33.8%) patients with
diabetic or non-diabetic hyperglycemia and 4 of the 29
(13.8%) patients with, speciﬁcally, diabetic hyperglycemia
would have been identiﬁed. In contrast, 70 of the 74 (94.6%)
patients with diabetic or non-diabetic hyperglycemia and all
of the 29 patients with, speciﬁcally, diabetic hyperglycemia
were identiﬁed on the basis of the 2-hour serum glucose
value obtained after an oral glucose tolerance test (Figure 1).
Considerable discordance in the accuracy of fasting and 2-
hour postload glucose for the identiﬁcation of impaired
glucoseregulationhasbeenobservedindiﬀerentpopulations
[13, 28]. Fasting glucose may have lower sensitivity in
younger individuals [13]. Additionally, IFG and IGT may
moreaccuratelyreﬂecthepatic and muscle insulin resistance,
respectively[14].Yet,non-alcoholicfattyliverdiseaseisasso-
ciated with both hepatic and peripheral insulin resistance
[29–31].
The oral glucose tolerance test is thought to be rather
cumbersome to perform in everyday clinical practice [14].
Our study indicates that non-alcoholic fatty liver disease
patients of older age, higher BMI, and lower HDL-C
should be prioritized in this regard. In two other similar
studies, older age and higher BMI have been associated
with abnormal oral glucose tolerance in young male non-
alcoholic fatty liver disease patients in China [32], and lower
HDL-C has been associated with diabetes mellitus in non-
alcoholic fatty liver disease patients in Hong Kong [33].
Besides, increased age and BMI are risk factors for more
severe disease or adverse prognosis in patients with non-
alcoholic fatty liver disease [2, 8, 9].
According to our ﬁndings, the value of an oral glucose
tolerance test, if performed in patients with non-alcoholic
fatty liver disease with appropriate risk factors, would be
ﬁrst to identify those with diabetic hyperglycemia. This
group should be managed as for type 2 diabetes, if the
diagnosis is conﬁrmed with a second positive relevant test.
An oral glucose tolerance test in selected patients with non-
alcoholic fatty liver disease can also identify those with
impaired glucose tolerance, which indicates an increased
risk for developing type 2 diabetes. Although the risk for
developing type 2 diabetes can also be determined by
considering patient characteristics that are more readily
available [34], the presence of impaired glucose regulation
signals additionally an increased risk for the development of
macrovascular complications [35]. Non-alcoholic fatty liver
disease patients with impaired glucose tolerance should be
encouraged to modify lifestyle factors (e.g., lose weight and
increasephysicalactivity)topreventthedevelopmentoftype
2 diabetes [14]. These measures would be also important for
preventing the progression of liver disease [36].
Some of the patients with impaired glucose tolerance
and additional risk factors for type 2 diabetes could also
be candidates to receive pharmacologic therapy, particularly
with metformin [14]. Pioglitazone might also be eﬀective
in this regard [37]. These insulin-sensitizing agents have
additionally shown promise for the treatment of biopsy-
proven non-alcoholic steatohepatitis in small clinical trials
[38, 39]. Whether non-alcoholic fatty liver disease patients
with impaired glucose tolerance represent appropriate can-
didates to receive such medications, on top of lifestyle
modiﬁcation, with the aim to prevent progression into type
2 diabetes and to non-alcoholic steatohepatitis and, also,
to decrease the overall cardiovascular risk, requires further
study.
Inconclusion,inourstudyofpatientswithnon-alcoholic
fatty liver disease, older age, higher BMI, and lower serum
levels of HDL-C independently predicted the presence of
hyperglycemia (deﬁned as IFG, IGT, or type 2 diabetes) that
was primarily identiﬁed through an oral glucose tolerance
test. Conclusively, we suggest that oral glucose tolerance
testing should be considered for patients with non-alcoholic
fatty liver disease with one or more of the above-mentioned
predictor factors for hyperglycemia to readily diagnose and
manage disorders of glucose metabolism.
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